Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China

References

• Araf Y, Akter F, Tang Y, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825–12. doi:10.1002/jmv.27588.
   PubMed Web of Science ®Google Scholar
• Loo K-Y, Letchumanan V. COVID-19: understanding the new variants of concern. Prog Micobes Mol Biol. 2022;5(1). doi:10.36877/pmmb.a0000282.
   Google Scholar
• Zhou Z, Zhu Y, Chu M. Role of COVID-19 vaccines in SARS-CoV-2 variants. Front Immunol. 2022;13:898192. doi:10.3389/fimmu.2022.898192.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400. doi:10.1056/NEJMoa2114255.
   PubMed Web of Science ®Google Scholar
• Walensky RP. CDC recommends Pfizer booster at 5 months, additional primary dose for certain immunocompromised children. 2022 Jan 4 [accessed 2022 Dec 21]. https://stacks.cdc.gov/view/cdc/113081.
   Google Scholar
• All adults to be offered COVID-19 boosters by end of January. Department of Health and Social Care; 2021 Nov 30 [accessed 2023 Jan 10]. https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-of-january.
   Google Scholar
• World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules. 2021 Dec 16 [accessed 2022 Dec 21]. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules.
   Google Scholar
• COVID-19 vaccine tracker. 2022 Dec 2 [accessed 2022 Dec 21]. https://covid19.trackvaccines.org/agency/who/.
   Google Scholar
• National Health Commission of the People’s Republic of China. Notice on the issuance of the work plan for vaccination in response to the recent outbreak of novel coronavirus infection. 2023 Apr 10 [accessed 2023 June 20]. http://www.nhc.gov.cn/xcs/zhengcwj/202304/c8db1a9da0204fdb87c88d7f70b284c0.shtml.
   Google Scholar
• Xinhua News Agency. These progress have been made in the development of a novel coronavirus vaccine in parallel with multiple technological routes. 2022 Oct 12 [accessed 2022 Dec 21]. http://www.gov.cn/xinwen/2022-10/12/content_5717961.htm.
   Google Scholar
• Rubin R. COVID-19 vaccine nasal spray. Jama. 2021;326(12):1138–. doi:10.1001/jama.2021.14996.
   Web of Science ®Google Scholar
• Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, Hober S, Gordon M, Blom K, Klingström J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med. 2022;387(14):1333–6. doi:10.1056/NEJMc2209651.
   PubMed Web of Science ®Google Scholar
• Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine. 2023;87:104402. doi:10.1016/j.ebiom.2022.104402.
   PubMed Web of Science ®Google Scholar
• Emily W. How nasal-spray vaccines could change the pandemic. Nature. 2022;609(7926):240–2. doi:10.1038/d41586-022-02824-3.
   PubMed Web of Science ®Google Scholar
• Knisely JM, Buyon LE, Mandt R, Farkas R, Balasingam S, Bok K, Buchholz UJ, D’Souza MP, Gordon JL, King DFL, et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report. NPJ Vaccines. 2023;8(1):53. doi:10.1038/s41541-023-00654-6.
   PubMed Web of Science ®Google Scholar
• Emily W. China and India approve nasal COVID vaccines — are they a game changer? Nature. 2022;609(7927):450. doi:10.1038/d41586-022-02851-0.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang P, Yuan L, Zhang L, Zhang L, Zhao H, Chen C, Wang X, Han J, Chen Y, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bull. 2022;67(13):1372–87. doi:10.1016/j.scib.2022.05.018.
   PubMed Web of Science ®Google Scholar
• Wantai Biopharmaceutical Company. Prompt announcements to get key data from phase III clinical trial of influenza virus vector COVID-19 vaccine for intranasal spray (Identifier: 2022-092). 2022 Oct 11 [accessed 2022 Dec 21]. https://www.ystwt.com/zxgg.
   Google Scholar
• Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. A phase III clinical trial of influenza virus vector COVID-19 vaccine for intranasal spray (DelNS1-2019-nCoV-RBD-OPT1). Identifier ChiCTR2100051391. 2021 Dec 4 [accessed 2023 June 18]. https://www.chictr.org.cn/showproj.html?proj=133897.
   Google Scholar
• Xia N, Zhu F, Huang S, Liu X, Chen Q, Zhuang C, Han J, Jaen A, Do TH, Peter J, et al. The efficacy and safety of an intranasal spray COVID-19 vaccine in a randomized double-blind placebo-controlled phase III trial during omicron period. Res Sq. 2023 Feb 19 [accessed 2023 June 20]. doi:10.21203/rs.3.rs-2407050/v1.
   Google Scholar
• The Joint Prevention and Control Mechanism of the State Council in Response to the Novel Coronavirus Pneumonia. Notice on the implementation plan for vaccination of second booster dose of COVID-19 vaccines. 2022 Dec 14 [accessed 2023 June 18]. http://www.nhc.gov.cn/xcs/zhengcwj/202212/acd8ba68d934488983909e81642dc337.shtml.
   Google Scholar
• National Health Commission of the People’s Republic of China. A notice on the issuance of the implementation plan for the second dose of the novel coronavirus vaccine. 2022 Dec 14 [accessed 2022 Dec 21]. http://www.nhc.gov.cn/xcs/yqfkdt/202212/acd8ba68d934488983909e81642dc337.shtml.
   Google Scholar
• Wantai Biopharmaceutical Company. Prompt announcement on the inclusion of the nasal spray influenza virus vector COVID-19 vaccine for emergency use (Identifier: 2022-102). 2022 Dec 6 [accessed 2023 June 18]. https://www.ystwt.com/zxgg/
   Google Scholar
• National Health Commission of the People’s Republic of China. Technical guidance on COVID-19 vaccination (First edition). 2021 Mar 29 [accessed 2023 Jun 18]. http://www.nhc.gov.cn/xcs/yqfkdt/202103/c2febfd04fc5498f916b1be080905771.shtml.
   Google Scholar
• Department of Health and Aged Care, Australian Government. Vaccination after COVID-19 infection. 2023 Apr 5 [accessed 2023 June 18]. https://www.health.gov.au/our-work/covid-19-vaccines/getting-your-vaccination/vaccination-after-covid-19-infection.
   Google Scholar
• WHO. Understanding the behavioural and social drivers of vaccine uptake WHO position paper - May 2022. Wkly Epidemiol Rec. 2022;97(20):209–24.
   Google Scholar
• Z J. jjPlot: some geom/stat functions to produce funny graphs. 2022 [accessed 2022 Dec 21]. https://github.com/junjunlab/jjPlot.
   Google Scholar
• Burki TK. Omicron variant and booster COVID-19 vaccines. Lancet Respir Med. 2022;10(2):e17. doi:10.1016/S2213-2600(21)00559-2.
   PubMed Web of Science ®Google Scholar
• Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10(8):749–60. doi:10.1016/S2213-2600(22)00131-X.
   PubMed Web of Science ®Google Scholar
• Flood EM, Ryan KJ, Rousculp MD, Beusterien KM, Block SL, Hall MC, Mahadevia PJ. A survey of children’s preferences for influenza vaccine attributes. Vaccine. 2011;29(26):4334–40. doi:10.1016/j.vaccine.2011.04.018.
   PubMed Web of Science ®Google Scholar
• Marien AG, Hochart A, Lagrée M, Diallo D, Martinot A, Dubos F. Parental acceptance of an intranasal vaccine: example of influenza vaccine. Archives de Pédiatrie. 2019;26(2):71–4. doi:10.1016/j.arcped.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Ryan KA, Filipp SL, Gurka MJ, Zirulnik A, Thompson LA. Understanding influenza vaccine perspectives and hesitancy in university students to promote increased vaccine uptake. Heliyon. 2019;5(10):e02604. doi:10.1016/j.heliyon.2019.e02604.
   PubMed Web of Science ®Google Scholar
• Wong E-Y, Qiu H, Chien WT, Wong J-L, Chalise HN, Hoang H-X, Nguyen HT, Chan P-S, Wong M-S, Cheung A-L, et al. COVID-19 vaccine willingness and related factors among health care workers in 3 Southeast Asian jurisdictions. JAMA Netw Open. 2022;5(8):e2228061. doi:10.1001/jamanetworkopen.2022.28061.
   PubMed Web of Science ®Google Scholar
• Li L, Ma Y, Li W, Tang G, Jiang Y, Li H, Jiang S, Zhou Y, Yang Y, Zhang T, et al. Caregiver willingness to vaccinate children with pneumococcal vaccines and to pay in a low-resource setting in China: a cross-sectional study. Vaccines [Internet]. 2022;10(11):1897. doi:10.3390/vaccines10111897.
   Web of Science ®Google Scholar
• Rong H, Lai X, Ma X, Hou Z, Li S, Jing R, Zhang H, Peng Z, Feng L, Fang H. Seasonal influenza vaccination and recommendation: the difference between general practitioners and public health workers in China. Vaccines [Internet]. 2020;8(2):265. doi:10.3390/vaccines8020265.
   Web of Science ®Google Scholar